Expert Interview
Discussing the potential of Sarepta Therapeutics’ investigational gene therapy, SRP-9001 (delandistrogene moxeparvovec) for the treatment of DMD with a pediatric neurologist.
Ticker(s): SRPTInstitution: Duke University
- Former Co-Director of Duke Children's Neuromuscular Program & Professor of Neurology and Pediatrics at Duke, recently made a career change and is now exclusively focused on clinical trials.
- Treated hundreds of neuromuscular patients, including 150 DMD patients of all ages in 2023
- Actively involved in clinical research and many trials with a focus on pedicatric neuromuscular diseases; PI on multiple DMD studies including an Exon 53 skipping specific study.
Roughly how many patients do you manage with DMD tumors?
Added By: sara_adminCan you talk about the clinical potential of delandistrogene moxeparvovec in patients with DMD?
Added By: sara_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Nirogacestat?
Added By: sara_adminWhat risk-benefit profile do you expect for SRP-9001 in terms of functional endpoints and biological endpoints (micro-dystrophin level)?
Added By: user717c8673How do you compare another recent NDA filing of vamorolone for DMD? Do you see them competing for the future standard of care, or used in combination?
Added By: user717c8673There are many clinical metrics to measure motor function as clinical endpoints, NSAA, TTSTAND, 6MWT, RRTW, etc.. Do you see them being used in combination or some are preferred over others? Do you see them used differently in different subgroups (e.g., by different age groups, NSAA may plateau after 9 yo)
Added By: user717c8673Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
